Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 24.43M P/E - EPS this Y 44.20% Ern Qtrly Grth -
Income -16.03M Forward P/E -1.54 EPS next Y 78.20% 50D Avg Chg -26.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -39.00%
Dividend N/A Price/Book 0.46 EPS next 5Y - 52W High Chg -61.00%
Recommedations 2.00 Quick Ratio 1.14 Shares Outstanding 1.57M 52W Low Chg 6.00%
Insider Own 3.02% ROA -29.25% Shares Float 240.49M Beta 0.41
Inst Own 5.48% ROE -44.67% Shares Shorted/Prior 19.69K/16.30K Price 1.08
Gross Margin - Profit Margin - Avg. Volume 77,466 Target Price 126.50
Oper. Margin - Earnings Date Nov 19 Volume 79,617 Change -2.70%
About Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Purple Biotech Ltd. News
11/15/24 Purple Biotech Reports Third Quarter 2024 Financial Results
11/05/24 Purple Biotech Unveils Promising Biomarker for Cancer Therapy
11/04/24 Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
10/25/24 Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/11/24 Purple Biotech Unveils CAPTN-3 Cancer Therapy
10/10/24 Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
09/18/24 Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
09/16/24 Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested
09/10/24 Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
08/30/24 Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
08/16/24 Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
07/25/24 Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
07/10/24 Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
07/02/24 Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
07/01/24 Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
06/27/24 Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
06/01/24 Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
06:30 AM Purple Biotech Reports First Quarter 2024 Financial Results
04/25/24 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
03/28/24 Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
PPBT Chatroom

User Image roachfood Posted - 51 minutes ago

$PPBT

User Image Wkdwalker Posted - 1 hour ago

$PPBT maybe more rockets will help

User Image Wkdwalker Posted - 1 hour ago

$PPBT ⬇️ trying hard 🤣

User Image APEDM Posted - 2 hours ago

$BLRX BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co. $PPBT HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target

User Image Dr_HIM Posted - 3 hours ago

$PPBT 🥱😴

User Image iambaron Posted - 3 hours ago

$PPBT I want to add but every time I add a couple hundred shares it drops coincidentally

User Image SeekingapeacefulpathMill Posted - 6 hours ago

$PPBT ✌️fity huge spread ? Why trade at 2.61 for 574 shares then next trade 2.50 for lady trade of 121 🤔

User Image stockwars Posted - 6 hours ago

$PPBT What is the purpose of all those 1 share buys?

User Image ThisWi11hurt Posted - 6 hours ago

$PPBT seems the stock is such a red hot POS people would rather pay 30-50% of share price just to hold for the chance of $5 in 2 months. Hedging upward commence

User Image Wkdwalker Posted - 7 hours ago

$PPBT

User Image allgoodstill Posted - 7 hours ago

$BLRX If you like Israeli scams, you can always buy some $PPBT.

User Image ThisWi11hurt Posted - 7 hours ago

$PPBT

User Image Stocksavior14 Posted - 8 hours ago

$PPBT are $2s our new $4.20s, at least for now, until it goes lower?

User Image Stocksavior14 Posted - 16 hours ago

$PPBT another crap day closing 5% down during market We need a miracle and $400+ per share just for any of this shit show for 4 years to have been worth it. All that lost time and money sitting stagnant🤦🏼‍♂️

User Image Smittysixty Posted - 20 hours ago

$PPBT 62K in volume today. That’s another top 25 volume day since Jan 2022. Make that 19 of the top 25 days occurring since the RC. We’re rapidly approaching the average daily volume that we had back in 2020 during the Pizza Boy Pump Period. Something is coming, and soon….IMO

User Image ThisWi11hurt Posted - 23 hours ago

$PPBT lots of signs that this is about to reverse hard in the chart. Ceo hyping the top line results as a major value driving event. Low float, Moves considerably on no volume.. foreign stock. That weird accumulation yesterday. I’ll expect to see this start to drift upward still on no volume

User Image SandblockBuyouts Posted - 1 day ago

$PPBT "good data always wins"

User Image HEnver Posted - 1 day ago

$PPBT Dr_HARM not posting charts, nor chill out gifs. -> we go up.

User Image kckc88 Posted - 1 day ago

$PPBT I think Jake Paul should fight Isaac next🥊

User Image Stocksavior14 Posted - 1 day ago

$PPBT we need more than $240 per share because of the massive reverse split. We need $400+ minimum 🤦🏼‍♂️

User Image Stocksavior14 Posted - 1 day ago

$PPBT what will the bulls excuses be if nothing major happens after we get the Topline data by end of year?? I’m sure they will say it’s super bullish and make up some crazy reasoning

User Image hueallday Posted - 1 day ago

$PPBT we hit 240 (split adjusted) on preclinical data...

User Image ra_VEEN Posted - 1 day ago

$PPBT go to 2.19 shithole

User Image ra_VEEN Posted - 1 day ago

$PPBT we should reverse split again

User Image ra_VEEN Posted - 1 day ago

$PPBT I think it’s broken

User Image roachfood Posted - 1 day ago

$PPBT If there’s another mid day volume spike today, I’m callin a traditional Thursday PR and an updated corporate presentation that collectively include enough crumbs to push us to $3.25 and a close of $2.75. I like to make predictions that most likely won’t come true… better than cruising easy street and “being right” any day.

User Image YamiDawg Posted - 1 day ago

$PPBT Damn today 1k shares moves us $0.04 but yesterday 120k didn’t move the needle. Lol. Nothing to see here. Oh wait a sell of 10 shares will drop us the same 4 cents. Lol.

User Image Smittysixty Posted - 1 day ago

$PPBT FUN FACT: If you look at the top 25 volume days since January 2022, 18 of them have occurred since the ratio change on September 17th. In other words, in the past three years, nearly 75% of the highest volume days have happened, recently, in the past three months. There's no denying that the volume since the ratio change has increased SIGNIFICANTLY. So, where's it going? We'll find out by February 15th at the latest in the next round of 13F’s. That’s if we make it that far 😊.

User Image coinspitter Posted - 1 day ago

$PPBT So worst case based on official communication: - PPBT gets multiple deals for the 3 development compounds, probably each with upfront payment in multiples of current market cap and we wait until an asset or several are marketable or the company is acquired? Different opinions?

User Image Watcher48 Posted - 1 day ago

$PPBT Can I see the list of upcoming dates again?

Analyst Ratings
HC Wainwright & Co. Buy Aug 19, 24
HC Wainwright & Co. Buy Jul 11, 24
HC Wainwright & Co. Buy May 21, 24
HC Wainwright & Co. Buy Apr 26, 24
Chardan Capital Buy Mar 7, 24
HC Wainwright & Co. Buy Mar 5, 24
HC Wainwright & Co. Buy Feb 27, 24
HC Wainwright & Co. Buy Nov 21, 23
HC Wainwright & Co. Buy Aug 31, 23